Dr. Koffman’s ASH 2021 Day 4 Highlights

[bkoffman]

Dr. Koffman’s ASH 2021 Day 4 Highlights: In this year’s Day 4 wrap-up, Dr. Koffman keeps us in touch with what currently stands front and center in the world of CLL-relevant clinical trials. His overview touches on combinations of novel agents, innovative treatment strategies, MRD status to guide therapy, new BTKis, new bispecific antibodies, the continuing menace of COVID-19, differences in treatment based on race, and more, reminding all of us that clinical trials ensure momentum and forward motion in CLL. Read Day 4 Highlights here. cllsociety.org/2021/12/ash-...

[BobbyFour]

Very encouraging. I particularly like this statement: “New bispecific antibodies, new cellular therapies, LP-118, a novel small molecule inhibitor of Bcl-2 and Bcl-Xl and many more new types of drugs are on their way.” It is very encouraging to me, especially as I near treatment, to think that there may be new tools available on the workbench in the future. Imagine a day when there are many case specific treatments available, and eventually combinations that none of the mutant cells can escape. It kind of reminds me of the history of antibiotics. But unlike bacterial pathogens, our cancer cells can’t pass resistance on via their offspring infecting other people - so for us, each step of progress in drug development will endure.